PERCUROS BV

Their core work

Percuros BV is a Dutch SME specializing in preclinical imaging, nanomedicine, and cancer diagnostics. They develop and validate nanoparticle-based tools for image-guided surgery, molecular imaging, and non-invasive cancer detection — particularly using exosome-based diagnostics and 19F MRI technologies. Their work bridges the gap between laboratory nanomedicine research and clinical application, serving as a translational partner that provides imaging expertise, in vitro testing capabilities, and nanoparticle characterization to international research consortia.

What they specialise in

How they've shifted over time

In the early period (2015–2018), Percuros focused on immunotherapy, antibody-drug conjugates, and image-guided surgery with projects like PRISAR and ISPIC, alongside exploratory work in aging and health tourism (CHARMED). From 2019 onward, the focus shifted decisively toward non-invasive diagnostics — exosome-based detection (BrEXo-Apt, Gl.EXO, BESG), 19F MRI technologies (NOVA-MRI, SENATOR), and active cancer monitoring as an alternative to surgery (CAST, PRISAR2). The trajectory shows a clear move from therapeutic intervention toward diagnostic tools and surveillance strategies.

Percuros is converging on liquid biopsy (exosomes) and advanced MRI for non-invasive cancer detection — expect future work combining these into integrated diagnostic platforms.

How they like to work

Percuros operates as both a consortium leader and an active specialist partner, with a near-equal split of 12 coordinated and 14 participated projects. With 127 unique partners across 19 countries, they function as a networking hub in the MSCA ecosystem, building new consortia rather than repeatedly working with the same teams. Their heavy involvement in MSCA training networks (ITN, RISE, IF) means they are experienced hosts for visiting researchers and well-practiced at managing international mobility-focused projects.

Percuros has built a broad European network of 127 unique partners across 19 countries, primarily through MSCA mobility programs. Their partnerships span universities, hospitals, and SMEs across Western and Southern Europe, with likely strong ties to cancer research centers given the thematic focus.

What sets them apart

Percuros is unusually prolific for an SME — 26 H2020 projects with 12 as coordinator is rare for a small private company. Their niche is providing preclinical imaging and nanoparticle expertise as a commercial partner within academic consortia, filling the translational gap that universities alone cannot bridge. They combine deep technical capability in cancer nanomedicine with strong MSCA network-building experience, making them an ideal partner for any consortium needing an SME with both scientific credibility and project management track record.

Highlights from their portfolio

• ELECTOR
  Largest single EC contribution (EUR 646K) and the only project under the Health pillar, focused on eHealth in rheumatology — an outlier from their cancer focus.
• PRISAR2
  A direct successor to PRISAR, showing Percuros can sustain and grow a research line — coordinator role in proactive cancer monitoring as alternative to surgery.
• BrEXo-Apt
  Exemplifies their emerging exosome diagnostics direction — non-invasive breast cancer diagnosis using aptamer-exosome technology, coordinated by Percuros.